Research from Quam Securities, Quam Securities

Quam Securities Research

Research from Quam Securities

Quam Securities

Since its inception in 1986, Quam Securities Limited (Quam Securities) has grown to become one of the few mid-tier securities brokerages in Hong Kong with global execution capabilities for both private and institutional clients. It boasts a well-established network in Greater China including Taiwan and in major world markets through the Global Alliance Partners (GAP). Quam Securities is well-positioned not only to harness and drive business within the China Tonghai International Financial Limited but also between China and the world markets.

Equity Bottom-Up

Sino Biopharmaceutical / Equity Bottom-Up

<ul><li>This licensing agreement demonstrates the company's R&D capabilities.</li><li>TQC3721 has the potential to become the first domestically developed inhaled dual PDE3/4 inhibitor approved in China.</li><li>We expect Sino Biopharma to achieve higher revenue from the innovative drug business.</li></ul>

This licensing agreement demonstrates the company's R&D capabilities.TQC3721 has the potential to become the first domestically developed inhaled dual PDE3/4 inhibitor approved in China.We expect Sino Biopharma to achieve higher revenue from the innovative drug business.

<ul><li>Hong Kong market commentary</li><li>A-share market commentary</li><li>Sino Biopharma revenue up 10.3% y/y in 2025</li></ul>

Hong Kong market commentaryA-share market commentarySino Biopharma revenue up 10.3% y/y in 2025

Quam Morning Note (27 Mar) - Sino Biopharma

Hong Kong

Sino Biopharmaceutical is a leading, innovation-driven pharmaceutical conglomerate in China, focusing on the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in therapeutic areas such as oncology, hepatology, respiratory, and cardiovascular diseases, offering both modernized Chinese and Western medicines. It was founded in 2000 and is headquartered in Wanchai, Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sino Biopharmaceutical (1177 HK)

Quam Morning Note 8 Jul - Sino Biopharma

This licensing agreement demonstrates the company's R&D capabilities. TQC3721 has the potential to become the first domestically developed...

Quam Securities

Quam Morning Note (27 Mar) - Sino Biopharma

Hong Kong market commentary A-share market commentary Sino Biopharma revenue up 10.3% y/y in 2025

Quam Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)